Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial

Blood (2024) 144 (Supplement 1): 3354.

https://doi.org/10.1182/blood-2024-201086

Published: 2024

Journal Articles

Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial

Blood (2024) 144 (Supplement 1): 1984.

https://doi.org/10.1182/blood-2024-204055

Published: 2024

Journal Articles

Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group

Selina J Chavda, Marquita Camilleri, Andrew Hall, Laura Clayton, Fatjon Dekaj, Dunsi Bolarinwa, Chantelle Hughes, Doina Levinte, Eileen M Boyle, Martin F Kaiser, Rachel O'Malley, Emma Williams, Andie Guy, Pinkie Chambers, Sandra CM Quinn, Rakesh Popat

Blood (2024) 144 (Supplement 1): 3792.2.

https://doi.org/10.1182/blood-2024-205315

Published: 2024

Journal Articles

Ultra High-Risk Multiple Myeloma Patients with Multi-Hit Tumours and SKY92 High Risk Signature Are at Increased Risk of Early Relapse Even When Treated with Extended Intensified Induction and Consolidation - Results from the Optimum/Muknine Trial

Martin F. Kaiser, Rachel Phillip, Andrew Hall, Amy Holroyd, Laura Bevington, Ruth M de Tute, Laura Clayton, Sadie Roberts, Graham Jackson, Gordon Cook, Richard S Houlston, Mark Drayson, Roger Owen, Guy Pratt, Sarah R Brown, Matthew W. Jenner

Blood (2023) 142 (Supplement 1): 881.

https://doi.org/10.1182/blood-2023-177896

Published: 2023

Journal Articles

Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial

Martin F. Kaiser, Andrew Hall, Isabelle Smith, Ruth M. de Tute, Sadie Roberts, Emma Ingleson, Kristian M Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Richard S. Houlston, Graham Jackson, Gordon Cook, Guy Pratt, Mark T Drayson, Roger G Owen, Sarah R Brown, Matthew W Jenner

Blood (2022) 140 (Supplement 1): 1833–1835.

https://doi.org/10.1182/blood-2022-159540

Published: 2022

Journal Articles

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, Dexamethasone (Dara-CVRd), V-Augmented Autologous Stem Cell Transplant (V-ASCT) and Dara-Vrd Consolidation in Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL) Compared with Myeloma XI/XI+ Trial Treatment for Uhir MM: The UK Optimum/Muknine Trial

Martin F. Kaiser, Andrew Hall, Katrina Walker, Nicola Newnham, Ruth M. de Tute, Sadie Roberts, Emma Ingleson, Kristian M Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham Jackson, Gordon Cook, Guy Pratt, Roger G Owen, Mark T Drayson, Sarah R Brown, Matthew W Jenner

Blood (2021) 138 (Supplement 1): 465.

https://doi.org/10.1182/blood-2021-144990

Published: 2021

Journal Articles

Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial

Matthew W Jenner, Andrew Hall, Sian E Faustini, Alexandra Pitchford, Ruth M. de Tute, Sadie Roberts, Emma Ingleson, Kristian M Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham Jackson, Guy Pratt, Gordon Cook, Roger G Owen, Sarah R Brown, Mark T Drayson, Martin F. Kaiser

Blood (2021) 138 (Supplement 1): 2699.

https://doi.org/10.1182/blood-2021-149268

Published: 2021

Journal Articles

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

Mamta Garg, MD FRCP, FRCPath, Andrew Hall, Matthew Jenner, MBBS, MRCP, FRCPath, Bhuvan Kishore, MB BS, MRCP, FRCPath, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Alexandra Pitchford, Louise Flanagan, PhD, Jamie B Oughton, MPhil, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Sarah R Brown, PhD MSc, BSc, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 1890.

https://doi.org/10.1182/blood-2019-126567

Published: 2019

Journal Articles

Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial

James Croft, MBBS, BSc, Andrew Hall, Amy L Sherborne, PhD, Katrina Walker, Sidra Ellis, Kim Sharp, Amy Price, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Louise Flanagan, PhD, Mamta Garg, MD FRCP, FRCPath, Suzana Couto, Maria Wang, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, William E Pierceall, PhD, Anjan Thakurta, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin F. Kaiser

Blood (2019) 134 (Supplement_1): 4327.

https://doi.org/10.1182/blood-2019-123640

Published: 2019

Journal Articles

Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients

Sarah R Brown, PhD MSc, BSc, Andrew Hall, Jessica Kendall, BSc, MSc, Emma Ingleson, Louise Flanagan, PhD, Holger W Auner, MD PhD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Mamta Garg, MD FRCP, FRCPath, Martin F. Kaiser

Blood (2019) 134 (Supplement_1): 5552.

https://doi.org/10.1182/blood-2019-123672

Published: 2019

Journal Articles

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)

Matthew Jenner, MBBS, MRCP, FRCPath, Amy L Sherborne, PhD, Andrew Hall, Vallari Shah, Katrina Walker, Sidra Ellis, Kim Sharp, Amy Price, James Croft, MBBS, BSc, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Louise Flanagan, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Ruth M De Tute, BSc,MSc, Roger G. Owen, MD, Guy Pratt, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin F. Kaiser

Blood (2019) 134 (Supplement_1): 3162.

https://doi.org/10.1182/blood-2019-123547

Published: 2019

Journal Articles

Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial

James Croft, BSc, MBBS, MRCP, Andrew Hall, Katrina Walker, Amy L Sherborne, PhD, Sidra Ellis, Amy Price, Debbie Sherratt, Sadie Reed, PhD, Charlotte Pawlyn, BA, PhD MBBChir, MRCP, FRCPath, Mamta Garg, Kevin Boyd, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin Kaiser, MD

Blood (2018) 132 (Supplement 1): 3274.

https://doi.org/10.1182/blood-2018-99-111835

Published: 2018

Journal Articles

Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone

James Croft, BSc, MBBS, MRCP, Andrew Hall, Katrina Walker, Amy L Sherborne, PhD, Kevin Boyd, Mamta Garg, Charlotte Pawlyn, BA, PhD MBBChir, MRCP, FRCPath, Debbie Sherratt, Sadie Reed, PhD, William E Pierceall, Gordon Cook, Anjan Thakurta, PhD, Sarah R Brown, PhD MSc, BSc, Martin Kaiser, MD

Blood (2018) 132 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2018-99-111823

Published: 2018

Journal Articles

Molecular Profiling of Relapsed and Refractory Myeloma Identifies Frequent Bi-Allelic Driver Events — Interim Results of the 'Myeloma UK Seven' Biomarker Trial

Amy L Sherborne, PhD, Vallari Shah, MBBS, Andrew Hall, Katrina Walker, Sidra Ellis, Farzana Begum, David C Johnson, James Croft, BSc, MBBS, MRCP, Jack Kendall, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Lilit Atanesyan, Suvi Savola, Louise Flanagan, Anjan Thakurta, PhD, Mamta Garg, MD, Gordon Cook, MD PhD, Kevin Boyd, Sarah Brown, Martin F Kaiser, MD

Blood (2017) 130 (Supplement 1): 1851.

https://doi.org/10.1182/blood.V130.Suppl_1.1851.1851

Published: 2017

Journal Articles

Bortezomib (Velcade), Thalidomide, Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial

Rakesh Popat, MBBS, PhD, Sarah R Brown, Louise M Flanagan, Andrew Hall, Bhuvan Kishore, MBBS, FRPATH, MRCP, Matthew Streetly, Heather E Oakervee, Simon L. Hallam, Matthew Smith, MBBS, MA, MRCP, MRCPath, MD, Kwee L Yong, MBChB, PhD, Gordon Cook, MD PhD, James D. Cavenagh, MD

Blood (2015) 126 (23): 1826.

https://doi.org/10.1182/blood.V126.23.1826.1826

Published: 2015

Journal Articles

The Genomic Landscape Of Lineage Switch Acute Leukemia

Blood (2013) 122 (21): 2552.

https://doi.org/10.1182/blood.V122.21.2552.2552

Published: 2013

Journal Articles

BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance

Srividya Swaminathan, B Tech, Huining Kang, PhD, Richard C. Harvey, PhD, Chuanxin Huang, PhD, Maike Buchner, PhD, Zhengshan Chen, MD, PhD, Huimin Geng, Andrew Hall, Kazuhiko Igarashi, PhD, William L. Carroll, MD, Cheryl L. Willman, MD, Ari Melnick, MD, Markus Muschen, MD, PhD

Blood (2012) 120 (21): 1300.

https://doi.org/10.1182/blood.V120.21.1300.1300

Published: 2012

Journal Articles

ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling

Lilian Kuster, Reinhard Grausenburger, Gerhard Fuka, Ulrike Kaindl, Gerd Krapf, Andrea Inthal, Georg Mann, Maximilian Kauer, Johannes Rainer, Reinhard Kofler, Andrew Hall, Markus Metzler, Lüder Hinrich Meyer, Claus Meyer, Jochen Harbott, Rolf Marschalek, Sabine Strehl, Oskar A. Haas, Renate Panzer-Grümayer

Blood (2011) 117 (9): 2658–2667.

https://doi.org/10.1182/blood-2010-03-275347

Published: 2011

Includes: Supplemental data

Journal Articles

Quantitative Proteomic Analysis Implicates An Altered B-Cell Differentiation State as a Mechanism Underlying GC-Resistance in An Acute Lymphoblastic Leukaemia (ALL) Cell Line Model.

Lindsay Nicholson, PhD, Caroline Evans, PhD, Elizabeth Matheson, M.Phil., Lynne Minto, Christopher Keilty, Andrew Hall, PhD, FRCPath, Christopher Redfern, PhD, Anthony Whetton, PhD, Julie Irving, PhD

Blood (2009) 114 (22): 1736.

https://doi.org/10.1182/blood.V114.22.1736.1736

Published: 2009

Journal Articles

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms

Francis H. Grand, Claire E. Hidalgo-Curtis, Thomas Ernst, Katerina Zoi, Christine Zoi, Carolann McGuire, Sebastian Kreil, Amy Jones, Joannah Score, Georgia Metzgeroth, David Oscier, Andrew Hall, Christian Brandts, Hubert Serve, Andreas Reiter, Andrew J. Chase, Nicholas C. P. Cross

Blood (2009) 113 (24): 6182–6192.

https://doi.org/10.1182/blood-2008-12-194548

Published: 2009

NARROW

Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial

Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial

Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group

Ultra High-Risk Multiple Myeloma Patients with Multi-Hit Tumours and SKY92 High Risk Signature Are at Increased Risk of Early Relapse Even When Treated with Extended Intensified Induction and Consolidation - Results from the Optimum/Muknine Trial

Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial

Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial

Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients

Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)

Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial

Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone

Molecular Profiling of Relapsed and Refractory Myeloma Identifies Frequent Bi-Allelic Driver Events — Interim Results of the 'Myeloma UK Seven' Biomarker Trial

Bortezomib (Velcade), Thalidomide, Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial

The Genomic Landscape Of Lineage Switch Acute Leukemia

BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance

ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling

Quantitative Proteomic Analysis Implicates An Altered B-Cell Differentiation State as a Mechanism Underlying GC-Resistance in An Acute Lymphoblastic Leukaemia (ALL) Cell Line Model.

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only